Effects of Baloxavir Marboxil Plus Neuraminidase Inhibitor vs Neuraminidase Inhibitor in High-risk Patients Hospitalized With Severe Influenza: A Post Hoc Analysis of the Flagstone Trial.

ABSTRACT:

Background

Combining baloxavir with neuraminidase inhibitors (NAIs) has not demonstrated significant benefits in severe influenza. High-risk populations with impaired viral clearance may represent the optimal candidates for this combination treatment.

Methods

We conducted a post hoc analysis of the Flagstone trial (NCT03684044), including patients hospitalized with severe influenza. Eligible participants met at least 1 of the following criteria: immunosuppression, diabetes, or chronic lung disease. Time to clinical improvement (TTCI), 28-day mortality, virological outcomes, and safety end points were assessed.

Results

Among the 143 patients included in the efficacy analysis, 92 received baloxavir in combination with NAI (dual antiviral group), while 51 received NAIs a

SUBMITTER: Yan M 

PROVIDER: S-EPMC12368417 | biostudies-literature | 2025 Aug

REPOSITORIES: biostudies-literature